Psychiatry and Neurology, Neurology · Freehold, NJ
NPI
1174507644
Since 2005
Specialty
Psychiatry and Neurology, Neurology
Code 2084N0400X
Group practices
2
Medicare group memberships
Hospitals
1
Hospital affiliations
901 W Main St Ste 364
Freehold, NJ, 07728
Phone (732) 729-4325
Groups this clinician bills Medicare through
Medicare paid, 2024
$11K
162 services
Medicare patients, 2024
77
Average age 63
Drug cost, 2024
$2.5M
912 prescriptions
Company payments, 2025
$2,676
From 16 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Caren G Marks was code 99214 (office e&m - established), 82 times for 54 patients. In total Caren G Marks billed 162 services in 4 codes, and Medicare paid $11K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2022-03-04.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Facility | 82 | 54 | $72.62 | $5,955 |
| 99213 Office E&M - Established | Facility | 71 | 49 | $53.48 | $3,797 |
By year: 2022 $9,325 for 141 services; 2023 $10K for 154 services; 2024 $11K for 162 services.
Medicare prescription drug claims, 2024
In 2024, the drug Caren G Marks prescribed most often to Medicare patients was Baclofen, with 98 prescriptions and refills. In total Caren G Marks wrote 912 Medicare prescriptions that cost $2.5M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Baclofen Generic | 98 | 243 | 40 | $2,078 |
| Gabapentin Generic | 80 | 170 | 34 | $1,685 |
| Dalfampridine Er Dalfampridine | 75 | 123 | 19 | $65K |
| Copaxone Glatiramer Acetate | 38 | 49 | Under 11 | $295K |
| Mayzent Siponimod | 36 | 70 | Under 11 | $680K |
| Alprazolam Generic | 30 | 30 | 15 | $91.62 |
| Tecfidera Dimethyl Fumarate | 28 | 32 | Under 11 | $304K |
| Tizanidine Hcl Generic | 27 | 71 | 11 | $872 |
| Carbamazepine Er Carbamazepine | 25 | 53 | Under 11 | $2,442 |
| Modafinil Generic | 25 | 25 | Under 11 | $765 |
| Dimethyl Fumarate Generic | 21 | 29 | Under 11 | $46K |
| Aubagio Teriflunomide | 19 | 21 | Under 11 | $187K |
| Amitriptyline Hcl Generic | 19 | 50 | Under 11 | $499 |
| Kesimpta Pen Ofatumumab | 16 | 24 | Under 11 | $230K |
| Tolterodine Tartrate Er Tolterodine Tartrate | 15 | 39 | Under 11 | $3,039 |
Brand drugs: 210 claims; generic drugs: 702 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Caren G Marks $2,676 ($2,676 in general payments such as food, travel and fees) from 16 companies. The largest payer was Biogen, Inc. with $658.
| Company | Payments | Amount |
|---|---|---|
| Biogen, Inc. BIIB | 29 | $658 |
| EMD Serono, Inc. MRK.DE | 19 | $363 |
| Novartis Pharmaceuticals Corporation NVS | 34 | $341 |
| TG Therapeutics, Inc. TGTX | 12 | $287 |
| Abbvie Inc. ABBV | 19 | $260 |
| Genentech USA, Inc. ROG.SW | 9 | $157 |
| Genzyme Corporation SNY | 7 | $127 |
| Amgen Inc. AMGN | 6 | $111 |
| Vanda Pharmaceuticals Inc. VNDA | 5 | $80.24 |
| Celgene Corporation BMY | 5 | $76.9 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.